



HealthLinx Limited

RESULTS FOR RELEASE TO THE MARKET

March 2012 Appendix 4C Commentary

26 July 2012, Melbourne: HealthLinx Limited (ASX:HTX) received delayed Grant Income, receipts from customers and funding from the US based investor group during the final quarter of the financial year. These sources of income, along with further receipts from customers and US based funding in the new financial year have maintained the company's cash position.

The company looks forward to the continued growth of its sales and royalties to strengthen its position going forward. HealthLinx aims to achieve this while continuing its foundation R&D and commercialisation activities in relation to OvPlex.

Appendix 4C attached.

Enquiries

Nick Gatsios (HealthLinx Limited) +61 3 9208 4200
Rudi Michelson (Monsoon Communications) +61 3 9620 3333

About HealthLinx Limited (ASX:HTX)

HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are:

- Ovarian cancer diagnostic (OvPlex) targeting US\$270m pa market
- Prostate Cancer targeting US\$350m pa market

A biomarker is a specific biochemical in the body that measures disease or the effects of treatment.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Name of entity

HealthLinx Limited

ABN

88 098 640 352

Quarter ended ("current quarter")

31st March 2012

Consolidated statement of cash flows

		Current quarter \$A'000	Year to date (9 months) \$A'000
Cash flows related to operating activities			
1.1	Receipts from customers	10	10
1.2	Payments for (a) staff costs	(61)	(210)
	(b) advertising and marketing	0	0
	(c) research and development	(243)	(756)
	(d) leased assets	0	0
	(e) other working capital	(384)	(1,184)
1.3	Dividends received		
1.4	Interest and other items of a similar nature received	2	2
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid	335	335
1.7	Other		172
		(341)	(1,631)
Net operating cash flows			

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (9 Months) \$A'000
1.8 Net operating cash flows (carried forward)	(341)	(1,631)
1.9 Cash flows related to investing activities		
Payment for acquisition of:		
(a) businesses (item 5)		
(b) equity investments		
(c) intellectual property		
(d) physical non-current assets		
(e) other non-current assets		
1.10 Proceeds from disposal of:		
(a) businesses (item 5)		
(b) equity investments		
(c) intellectual property		
(d) physical non-current assets		
(e) other non-current assets		
1.11 Loans to other entities		
1.12 Loans repaid by other entities		
1.13 Other (provide details if material) VSA Grant Funding	0	75
Net investing cash flows		
1.14 Total operating and investing cash flows	0	75
1.15 Cash flows related to financing activities		
Proceeds from issues of shares, options, etc.	459	1,626
1.16 Proceeds from sale of forfeited shares		
1.17 Proceeds from borrowings		
1.18 Repayment of borrowings		
1.19 Dividends paid		
1.20 Other (provide details if material)		
Net financing cash flows	459	1,626
Net increase (decrease) in cash held	118	70
1.21 Cash at beginning of quarter/year to date	62	110
1.22 Exchange rate adjustments to item 1.20		
1.23 Cash at end of quarter	180	180

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	61
1.25	Aggregate amount of loans to the parties included in item 1.11	
1.26	Explanation necessary for an understanding of the transactions <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> Payments made to non-executive directors </div>	

Non-cash financing and investing activities

- 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

- 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	(a) 8,380	620
3.2	Credit standby arrangements	0	0

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter \$A'000	Previous quarter \$A'000
4.1	Cash on hand and at bank	15	53
4.2	Deposits at call	165	9
4.3	Bank overdraft	0	0
4.4	Other (Credit cards)	0	0
Total: cash at end of quarter (item 1.23)		180	62

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	
5.2	Place of incorporation or registration	
5.3	Consideration for acquisition or disposal	
5.4	Total net assets	
5.5	Nature of business	

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:



Date:26th July 2012.....
 (Company secretary)
 Print name: Mal Lucas-Smith

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.
 - 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
 - 9.2 - itemised disclosure relating to acquisitions
 - 9.4 - itemised disclosure relating to disposals
 - 12.1(a) - policy for classification of cash items
 - 12.3 - disclosure of restrictions on use of cash
 - 13.1 - comparative information
3. **Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.
4. Financing Facilities Available – a funding agreement with Dutchess Capital was entered in to in June 2011; however no funds had been draw down from this source as at 30 June. The SpringTree Global Investors LLC Facility was terminated on 13 July 2011. Further funding opportunities in the USA are also being investigated.